FDA issues third warning letter to Empower Pharmacy over GLP-1 weight-loss treatments

The U.S. Food and Drug Administration sent a formal warning letter to Empower Pharmacy, a compounder based in Houston, concerning its GLP-1 weight-loss products.

The notice marks the company's third FDA warning in under two years, indicating ongoing compliance concerns with the manufacturing or distribution of the GLP-1 therapies.

The FDA letter does not detail specific violations, but such warnings typically require the firm to address the cited issues promptly to avoid further regulatory action.